Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

How Working Past 62 Could Permanently Change Your Social Security Benefit

View original at fool.com
Motley Fool - Stock Analysis Title: How Working Past 62 Could Permanently Change Your Social Security Benefit Date: 2026-04-04 19:15 Source: https://www.fool.com/retirement/2026/04/04/how-working-past-62-could-permanently-change-your/?source=iedfolrf0000001 <p>Retirement is the goal everyone works toward…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Claiming Social Security at age 62 reduces monthly benefits for life

    60% confidence

  • Age 62 is the earliest age you can currently claim Social Security retirement benefits

    60% confidence

  • The median U.S. household approaches Social Security eligibility with just $185,000 in retirement savings

    60% confidence

  • Working past age 62 can permanently change Social Security benefits in three ways

    60% confidence

  • Social Security is an important financial crutch for most retirees given median retirement savings of $185,000

    60% confidence

  • The median U.S. household approaches Social Security eligibility with just $185,000 in retirement savings

    60% confidence

  • Social Security is an important financial crutch for most retirees given median retirement savings levels

    60% confidence

  • Claiming Social Security at 62 reduces your monthly benefits for life

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
How Working Past 62 Could Permanently Change Your Social Security Benefit — Source | Via News | Via News